Inflammatory Bowel Disease Research Studies at Baylor College of Medicine
Research is a key mission of the Inflammatory Bowel Disease Center at Baylor College of Medicine. Only through continued research with participation of patients with Crohn's disease and ulcerative colitis will we be able to advance the understanding and improve the treatment of inflammatory bowel disease. We have a range of opportunities for patients with inflammatory bowel disease to participate in research from filling out questionnaires to providing blood samples to trials of new drugs.
Baylor College of Medicine is an official member of the Crohn’s and Colitis Foundation of America’s (CCFA) Clinical Research Alliance. This allows our site to be involved in multi-centered studies that are headed by the CCFA.
- MERIT-UC (H-27285)- This is a clinical trial using methotrexate (injection) to treat ulcerative colitis
- Santarus-UC (H-30601)- This is a clinical trial using extended release budesonide (oral) to treat ulcerative colitis
- UNITI- CD (H-28485)- This is a clinical trial using ustekinumab (infusion/injection) to treat Crohn's disease
- ANDANTE- CD (H-31018) This is a clinical trial using an Interleukin 6-antagonist (injection) to treat Crohn's disease
- TRUST-1- CD (H-31022) This is a clinical trial using trichuris suis ova (porcine whipworm) to treat Crohn's disease
We are conducting registry studies to monitor those patients who are taking biologic medications. Participation in these studies do not require a change in how your doctor is treating your Crohn's disease or ulcerative colitis. They are ways we gather information on the safety of medications that are currently approved for use in Crohn's disease or ulcerative colitis:
- CD INFORM - This is an observational study designed to obtain long-term safety data on patients with Crohn’s Disease being treated with natalizumab (Tysabri). The study duration is five years from enrollment and subjects will be followed during normal physician visits.
- SECURE - This is an observational study designed to track safety outcomes of patients who have taken certolizumab pegol (Cimzia) for the treatment of Crohn’s disease compared to a non-Cimzia control population. The study duration is 10 years and subjects will be followed during normal physician visits and through web surveys and telephone calls.
- The Multi-Center African American Inflammatory Bowel Disease Study (MAAIS): This is a study sponsored by the National Institutes of Health (NIH) to identify genes involved in Crohn's disease and ulcerative colitis and how they may differ by race. This study involves a one time blood draw and the completion of a single questionnaire.
- Impact of diet and nutrition on inflammatory bowel disease: This study is evaluating what impact diet and nutrition has on Crohn's disease or ulcerative colitis including whether certain dietary habits can cause Crohn's disease or ulcerative colitis, what nutritional deficiencies are seen in patients with Crohn's disease or ulcerative colitis and whether dietary modifications can alter the symptoms/course of the disease. The study involves the completion of a single questionnaire.
For more information on Inflammatory Bowel Disease-related studies at BCM:
- Please contact our research coordinator at firstname.lastname@example.org